Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Analysts give Pacira an average rating of “Hold” (from six analysts: 1 sell, 2 hold, 3 buy) with a 12‑month average price target of $30.25.
• There were recent insider sales: Jonathan Slonin sold 3,261 shares at $22.82 and SVP Lauren Riker sold 4,000 shares at $20.81, reducing their ownership (insiders now own 6.40% of the stock).
• Pacira missed quarterly estimates, reporting EPS of $0.57 vs. a $0.85 consensus and revenue of $196.87M vs. $201.93M; the company has a market cap of about $974M and a P/E of 160.4.

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have been given an average rating of "Hold" by the six analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $30.25.

Several research analysts have recently issued reports on PCRX shares. Barclays reduced their price target on Pacira BioSciences from $27.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 26th. Zacks Research upgraded Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Tuesday, April 7th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Pacira BioSciences in a report on Monday, December 29th. HC Wainwright reiterated a "buy" rating and set a $38.00 target price on shares of Pacira BioSciences in a report on Friday, January 9th. Finally, Wall Street Zen lowered Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 28th.

Insider Activity

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the transaction, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $20.81, for a total value of $83,240.00. Following the transaction, the senior vice president owned 52,313 shares in the company, valued at approximately $1,088,633.53. This represents a 7.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 6.40% of the company's stock.

Institutional Trading of Pacira BioSciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Hantz Financial Services Inc. raised its stake in shares of Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company's stock valued at $29,000 after purchasing an additional 721 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in shares of Pacira BioSciences by 5,900.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company's stock valued at $39,000 after purchasing an additional 1,475 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Pacira BioSciences in the 4th quarter valued at about $48,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Pacira BioSciences in the 4th quarter valued at about $51,000. Finally, Global Retirement Partners LLC raised its stake in shares of Pacira BioSciences by 479.4% in the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company's stock valued at $52,000 after purchasing an additional 1,678 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Stock Up 1.1%

NASDAQ:PCRX opened at $24.06 on Tuesday. Pacira BioSciences has a 12-month low of $18.80 and a 12-month high of $27.64. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $974.19 million, a P/E ratio of 160.40 and a beta of 0.19. The stock's fifty day simple moving average is $22.50 and its 200-day simple moving average is $23.09.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.28). Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The company had revenue of $196.87 million during the quarter, compared to the consensus estimate of $201.93 million. During the same quarter in the prior year, the business earned $0.91 earnings per share. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. Equities research analysts expect that Pacira BioSciences will post 2.41 earnings per share for the current year.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.